Biological
Saponin QA-21V1 clinical trials
Also written QS21.
- studies test it
- 29
- open now
- 2
- in phase 3
- 1
- first study started
- 1996
Keep track of what changes. Save the saponin QA-21V1 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 1998 (4)
| Year | Studies |
|---|---|
| 1996 | 1 |
| 1998 | 4 |
| 1999 | 2 |
| 2000 | 3 |
| 2001 | 1 |
| 2002 | 1 |
| 2007 | 3 |
| 2009 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 19
- Phase 2
- 7
- Phase 3
- 1
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 25
Memorial Sloan Kettering Cancer Center (10) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · U.S. Army Medical Research and Development Command (4) · Pfizer (4) · Henry M. Jackson Foundation for the Advancement of Military Medicine (2) · University of Virginia (1) · Fox Chase Cancer Center (1) · Ohio State University Comprehensive Cancer Center (1)
Often tested with
Tested in the same studies.
Monophosphoryl lipid A (6) · Vanutide cridificar (4) · HIV Envelope Protein gp120 (2) · GM2-KLH Vaccine (2) · IHV01 (1) · A244 (1) · Incomplete Freund's adjuvant (1) · Tetanus Peptide Melanoma Vaccine (1)
Studies
Open first, then newest update. How each study uses saponin QA-21V1 is read from its arms, and is right about nine times in ten.
Testing it · 29
- RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEVRecruitingPhase 1Henry M. Jackson Foundation for the Advancement of Military MedicineNCT06484335Written as ALFQ
- BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ TransplantsRecruitingPhase 1Ohio State University Comprehensive Cancer CenterNCT06741072Written as QS21
- Safety and Immunogenicity of CJCV2 With and Without ALFQCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT05500417Written as ALFQ
- HIV Vaccine in HIV-uninfected AdultsCompletedPhase 1U.S. Army Medical Research and Development CommandNCT04658667Written as ALFQ
- PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19CompletedPhase 1U.S. Army Medical Research and Development CommandNCT04784767Written as 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
- Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV RemissionWithdrawnPhase 1Henry M. Jackson Foundation for the Advancement of Military MedicineNCT05769569Written as ALFQ
- Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate CancerCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00579423Written as QS21
- A Trial For The Study of Falciparum Malaria Protein 013 Administered Via Intramuscular Injection in Healthy AdultsStatus unknownPhase 1U.S. Army Medical Research and Development CommandNCT04268420Written as ALFQ
- A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001044Written as QS-21
- A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001096Written as QS-21
- A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001052Written as QS-21
- Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected WomenWithdrawnPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000809Written as QS-21
- A Trial For The Study of Falciparum Malaria Protein 014 Administered Via Intramuscular Injection in Healthy AdultsStatus unknownPhase 1U.S. Army Medical Research and Development CommandNCT04296279Written as ALFQ
- Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's DiseaseCompletedPhase 2PfizerNCT00955409Written as ACC-001(3µg) + QS21
- Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast CancerCompletedNot applicableMemorial Sloan Kettering Cancer CenterNCT00470574Written as QS21
- A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's DiseaseTerminatedPhase 2PfizerNCT00960531Written as ACC-001+ QS21 (3mcg)
- Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's DiseaseCompletedPhase 2PfizerNCT00479557Written as ACC-001 + QS-21
- Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's DiseaseCompletedPhase 2PfizerNCT00498602Written as ACC-001 + QS-21
- Vaccine Therapy in Treating Patients at High Risk for Breast Cancer RecurrenceCompletedNot applicableMemorial Sloan Kettering Cancer CenterNCT00030823Written as QS21
- Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedPhase 1University of VirginiaNCT00003224Written as QS21
See all 29 studies that test saponin QA-21V1 →
Given in every arm · 1 — saponin QA-21V1 is usual care beside what is tested
Codes
What other systems call saponin QA-21V1 · ClinicalTrials.gg INT003688
- MeSH (NLM) C078785saponin QA-21V1One source NLM
- UNII (FDA) 61H83WZX3UQUILLAJA SAPONIN (QS-21)Confirmed FDA, NLM
- RxNorm 2002417One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C078785 | saponin QA-21V1 | One source NLM |
| UNII (FDA) | 61H83WZX3U | QUILLAJA SAPONIN (QS-21) | Confirmed FDA, NLM |
| RxNorm | 2002417 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.